Skip to content
ChickenStockChickenStock
ResearchADPT
Adaptive Biotechnologies logo

Adaptive Biotechnologies (ADPT) stock

NASDAQ

$29.05-1.46%(-0.43)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-67.23x

Net loss — not comparable

P/B

26.74x

P/S

15.74x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue decreased 10.6% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • RUBINSTEIN JULIEPresident and COO · Nov 13, 2026Open-market sale11,466 shares · $332K
    Avg. price $28.93377,802 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 13, 2026Option exercise11,466 shares · $139K
    Avg. price $12.14389,268 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 12, 2026Open-market sale11,881 shares · $349K
    Avg. price $29.4377,802 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 12, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 11, 2026Open-market sale11,881 shares · $366K
    Avg. price $30.8299
    Show 2 price lots
    • 6,898 shares × $31.22$215K
    • 4,983 shares × $30.29$151K
  • BOBULSKY SUSANChief Commercial Officer, MRD · Nov 11, 2026Open-market sale1,875 shares · $60K
    Avg. price $32387,475 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 11, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 10, 2026Open-market sale11,881 shares · $351K
    Avg. price $29.5195
    Show 2 price lots
    • 9,981 shares × $29.35$293K
    • 1,900 shares × $30.41$58K
  • RUBINSTEIN JULIEPresident and COO · Nov 10, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 9, 2026Open-market sale11,881 shares · $358K
    Avg. price $30.1184
    Show 3 price lots
    • 8,381 shares × $30.15$253K
    • 2,400 shares × $30.58$73K
    • 1,100 shares × $28.87$32K
  • RUBINSTEIN JULIEPresident and COO · Nov 9, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • ROBINS CHAD MCEO and Chairman · Nov 9, 2026Gift100,000 shares · $0
    Avg. price $02,080,518 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 6, 2026Open-market sale11,881 shares · $327K
    Avg. price $27.4841
    Show 2 price lots
    • 8,400 shares × $27.32$229K
    • 3,481 shares × $27.88$97K
  • RUBINSTEIN JULIEPresident and COO · Nov 6, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 5, 2026Open-market sale11,881 shares · $315K
    Avg. price $26.5255
    Show 3 price lots
    • 5,926 shares × $26.1$155K
    • 5,455 shares × $26.88$147K
    • 500 shares × $27.7$14K
  • RUBINSTEIN JULIEPresident and COO · Nov 5, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 4, 2026Open-market sale11,881 shares · $313K
    Avg. price $26.3239
    Show 2 price lots
    • 7,881 shares × $26.6$210K
    • 4,000 shares × $25.78$103K
  • RUBINSTEIN JULIEPresident and COO · Nov 4, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 3, 2026Open-market sale11,881 shares · $309K
    Avg. price $25.98377,802 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 3, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Nov 2, 2026Open-market sale11,881 shares · $303K
    Avg. price $25.4715
    Show 2 price lots
    • 9,296 shares × $25.23$235K
    • 2,585 shares × $26.34$68K
  • RUBINSTEIN JULIEPresident and COO · Nov 2, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Oct 30, 2026Open-market sale11,881 shares · $318K
    Avg. price $26.7314
    Show 2 price lots
    • 9,486 shares × $26.55$252K
    • 2,395 shares × $27.45$66K
  • RUBINSTEIN JULIEPresident and COO · Oct 30, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Oct 29, 2026Open-market sale11,881 shares · $336K
    Avg. price $28.27377,802 shares held after
  • RUBINSTEIN JULIEPresident and COO · Oct 29, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Oct 28, 2026Open-market sale11,881 shares · $338K
    Avg. price $28.4477
    Show 2 price lots
    • 11,681 shares × $28.44$332K
    • 200 shares × $28.9$6K
  • RUBINSTEIN JULIEPresident and COO · Oct 28, 2026Option exercise11,881 shares · $144K
    Avg. price $12.14389,683 shares held after
  • RUBINSTEIN JULIEPresident and COO · Oct 27, 2026Open-market sale8,881 shares · $244K
    Avg. price $27.53377,802 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Adaptive Biotechnologies (ADPT) stock information

NASDAQ

Adaptive Biotechnologies (ADPT) is listed on NASDAQ. Its market capitalization is about $4.7B. On trailing-twelve-month earnings the P/E ratio is -67.23, and the P/B ratio is 26.74. Return on equity is -39.8%. These figures are computed in-house from official filings and are reference information only.

Adaptive Biotechnologies — frequently asked questions

What is the P/E ratio of Adaptive Biotechnologies (ADPT)?
On a trailing-twelve-month basis, ADPT trades at a P/E ratio of -67.23. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Adaptive Biotechnologies?
ADPT has a market capitalization of about $4.7B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.